KPTI/ 10/13/2025 · 7:24 AM H.C. Wainwright Upgrades Karyopharm to Buy on Strategic Financing H.C. Wainwright upgrades Karyopharm to Buy with $15 price target following strategic financing that extends cash runway beyond Phase 3 SENTRY trial results.